Quality of Substances for Pharmaceutical Use: The EDQM Certification of Suitability to the European Pharmacopoeia Monographs (CEP) Dr. Susanne Keitel DIA.

Slides:



Advertisements
Similar presentations
EPAA Conference 5 November 2007 Georgette LALIS Enterprise and Industry DG European Commission The international dimension of regulatory acceptance.
Advertisements

Registration in Europe Current situation and future outlook Thomas K ü rner, M.D. Nippon Boehringer Ingelheim Co., Ltd.
Dr. Raghuveer Pharma Consultants D R P C Quality. Perfection. Confidentiality. D R P C Quality. Perfection. Confidentiality. 1.
Current Issues & Challenges in the Development of Pharmacopoeial Monographs: European Pharmacopoeia Dr. Susanne Keitel European Directorate for the Quality.
Special populations- What makes them so special? AGAH Association for Applied Human Pharmacology Annual meeting 2004 Berlin 29. Februar 2004 Birka Lehmann.
BROMI Variations – An Industry Perspective
DR MACIEJ JUNKIERT PRACOWNIA BADAŃ NAD TRADYCJĄ EUROPEJSKĄ Guide for Applicants.
1 XXXXXXXXXXXXXXXXXXX, Malaysia, XXXXXX September, S.3.2 Impurities, Malaysia, 29 September 2011 Options for submitting API data to support.
Introduction to PPDs Regulatory requirements and rationale.
1 Future of NamGIS Johan van Rensburg Polytech 14 October 2005.
Procedure under the Merger Regulation. Procedure – legal documents The Merger Regulation Art. 4 – notification of concentration Art. 7 – suspension of.
Sultan Ghani WHO Prequalification Programme of Priority Essential Medicines, October 2010, Abu Dhabi, U.A.E. Active Pharmaceutical Ingredient Master.
Office of Inspector General (OIG) Internal Audit
Slide 1 of 19D.K. Mubangizi, Dar Es Salaam Sept Training Workshop for Evaluators from National Medicines Regulatory Authorities in East African Community.
Sultan Ghani WHO Prequalification Programme of Priority Essential Medicines, October 2010, Abu Dhabi, U.A.E. Variations Maintenance of Prequalified.
Variations to Prequalified Medicines Rutendo Kuwana Workshop on WHO prequalification requirements for reproductive health medicines, Jakarta, October 2009.
EXCiPACT TM Certification 3rd Party Certification for Pharmaceutical Excipient Suppliers EFCG Update at CPhI, 9 th October 2012 Frithjof Holtz, Merck KGaA.
ZHRC/HTI Financial Management Training
Structure of Dossier of Medicinal Product- Q part
European Medicines Agency Activities Related to API’s
API Inspections: the EDQM experience 29 March 2010
Post approval changes- Variations Mercy Acquaye. Presentation Outline Introduction to Guidance Classification of changes Approval of changes Definitions.
S3: Module D Physikalisch-Technische Bundesanstalt Session 3: Conformity Assessment Module D Peter Ulbig, Harry Stolz Belgrade, 31 October.
1 International API Inspection Pilot Program Olivier Gross Scientific Administrator EMEA DIA International Conference Quality of Active Pharmaceutical.
Supported by a sector group of Presented by The APIC Audit Programme Thursday, 13 October 2005 Parallel Session The APIC Audit Programme presented by Dr.
Organization and Implementation of a National Regulatory Program for the Control of Radiation Sources Staffing and Training.
Jean-Marc Spieser, 23/09/09 ©2009 EDQM, Council of Europe, All rights reserved 1 Principles of Article 58 - possible support to 3rd countries for licensing.
PRODUCT TRANSFER.
CCAB Training Providers Event 17 November 2008 Reviews Required by QAC Heather Briers Director Chartered Accountants Regulatory Board.
Oilpalm.wildasia.org RSPO SCC Standard Group Certification (Part 3) RSPO LEAD AUDITOR SERIES SCCS M2c May 2013.
Information on the Certification Procedure Dr P. Poukens-Renwart Certification of Substances Division, EDQM P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council.
CONFIDENTIAL ©2014 PAREXEL INTERNATIONAL CORP. ALL RIGHTS RESERVED. THE PRACTICE OF REGULATORY INTELLIGENCE: CASE STUDIES OMICS 5 th International Pharmaceutical.
Project overview: objectives, work programme & management guidelines FIRST MEETING OF EUROPEAN POLICY CORE GROUP Thursday, 03 March 2005 in Berlin PRESENTATION.
Reporting Guidelines (FP5) Karen Fabbri Scientific Officer Natural & Technological Hazards DG Research European Commission Brussels
1 Impurities: Positions of the regulatory authorities (like FDA and EMA) worldwide Dr. Christian Zeine, Warsaw, Nov 18, 2014 Science for a safer world.
DMF Procedures and Communication between API, FP Manufacturers and Regulatory Authorities Jean-Louis ROBERT National Health Laboratory L – 1011 LUXEMBOURG.
Monograph Development Process for the European Pharmacopoeia: How to participate in the work programme of the European Pharmacopoeia Dr Claude Coune Head.
WORKSHOP, Nicosia 2-3rd July 2008 “Extension of SAFETY & QUALITY Common Requirements to the EMAC States” Item 3 : Regulatory Context Peter Stastny EUROCONTROL.
Principles of quality control of registered medicines, non- registered medicines and counterfeits of medical products Jean-Marc Spieser, Head of Department.
1 Workshop on the Directive 96/61/EC concerning (IPPC) Integrated pollution prevention and control INFRA Public participation & access to environmental.
Meeting for EU Generic Manufacturers and EU MA holders for generic medicines, Copenhagen, 26 November 2009 Generics approved by stringent regulatory authorities:
Company Confidential Registration Management Committee (RMC) AS9104/2A Presentation San Diego, CA January 17, 2013 Tim Lee The Boeing Company 1 Other Party.
© AL IPA/EDQM/IDMA Symposium 2007, All rights reserved The Ph. Eur. policy on impurities Dr Andrea Lodi Deputy Head, Laboratory Department, EDQM, Council.
Ivowen Ltd1 Ivowen Limited Preparation and Submission of a Traditional Herbal Medicinal Product Application.
Current Issues & Challenges in the Development of Pharmacopoeial Monographs: Some New Challenges in the Impurities Arena Dr. Susanne Keitel European Directorate.
International Atomic Energy Agency Roles and responsibilities for development of disposal facilities Phil Metcalf Workshop on Strategy and Methodologies.
IPA-EDQM Mumbai 11/2007 ©2007 EDQM, Council of Europe 1 Content of the application for a CEP Hélène BRUGUERA Deputy Head Certification of Substances Division.
Application procedure From theory to practice Dieter H. Henzler, Steinbeis-Transfercenter Cultural Resources Management, Berlin.
organization – status 2015 – scheme – integrity program – strategy
International conference Quality of Active Pharmaceutical Ingredients Hyderabad, September 2009 API Inspections: the EDQM experience – 7 September.
VICH General Principles and current update of VICH Outreach Forum activity 1.
VICH Training Strategy Steven D. Vaughn, DVM Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine U.S. Food and Drug Administration.
Overview of the EU regulatory system and governance
China EU Pharmaceutical Forum
DMF Procedures and Communication between API, FFP Manufacturers and Regulatory Authorities Jean-Louis ROBERT National Health Laboratory L – 1011 LUXEMBOURG.
Harmonised use of accreditation for assessing the competence of various Conformity Assessment Bodies Dr Andreas Steinhorst, EA ERA workshop 13 April 2016,
Good Laboratory Practice - general information Pirkko Puranen Senior Inspector, Ph.D. Inspectorate.
European Life Sciences Infrastructure for Biological Information ELIXIR Collaboration Agreement Template ELIXIR/2014/10 Vera Herkommer.
POST APPROVAL CHANGE MANAGEMENT PROTOCOLS IN THE EUROPEAN UNION
process and procedures for assessments
Dr Pascale POUKENS-RENWART Scientific Officer
Periodic Safety Update Reports (PSUR)
Information on Medicinal Products
PREPARATION FOR GMP INSPECTION
UK Legal Requirement for Notification of Serious Breaches of Good Clinical Practice or The Trial Protocol John Poland, PhD Senior Director, Regulatory.
CONDITIONAL MARKETING AUTHORISATION
GMP Inspection Process
Institutional changes The role of Bilateral Oversight Boards
The European Pharmacopoeia and Pharmeuropa
SID & GP MINPROMTORG OF RUSSIA Corporate Communication Center
Presentation transcript:

Quality of Substances for Pharmaceutical Use: The EDQM Certification of Suitability to the European Pharmacopoeia Monographs (CEP) Dr. Susanne Keitel DIA Workshop on CEPs Hyderabad, 5 September 2009

Dr. Susanne Keitel, 05/09/2009 ©2009 EDQM, Council of Europe, All rights reserved 2 Summary Legal Background CEP versus ASMF How it works How to apply Certification Inspection Programme Exchanging information/advice, communication opportunities

Dr. Susanne Keitel, 05/09/2009 ©2009 EDQM, Council of Europe, All rights reserved 3 Legal Background Directive 2003/63/EC “Whereases” (5) With respect to the quality part of the dossier, all monographs including general monographs and general chapters of the European Pharmacopoeia are applicable.

Dr. Susanne Keitel, 05/09/2009 ©2009 EDQM, Council of Europe, All rights reserved 4 Directive 2003/63/EC Chapter 3.2 Content: basic principles and requirements (5) The monographs of the European Pharmacopoeia shall be applicable to all substances, preparations and pharmaceutical forms appearing in it. In respect of other substances, each Member State may require observance or its own national pharmacopoeia…

Dr. Susanne Keitel, 05/09/2009 ©2009 EDQM, Council of Europe, All rights reserved 5 Directive 2003/63/EC ….However, where a material in the EP… has been prepared by a method liable to leave impurities not controlled in the pharmacopoeia monograph, these impurities and their maximum tolerance limits must be declared and a suitable test procedure must be described. In cases where a specification contained in a monograph of the EP… might be insufficient to ensure the quality of the substance, the competent authorities may request more appropriate specifications from the marketing authorisation holder…

Dr. Susanne Keitel, 05/09/2009 ©2009 EDQM, Council of Europe, All rights reserved 6 Directive 2003/63/EC … The competent authorities shall inform the authorities responsible for the pharmacopoeia in question. The marketing authorisation holder shall provide the authorities of that pharmacopoeia with the details of the alleged insufficiency and the additional specifications applied.

Dr. Susanne Keitel, 05/09/2009 ©2009 EDQM, Council of Europe, All rights reserved 7 Directive 2003/63/EC (7) Where the active substance and/or raw and starting material or excipient(s) are the subject of a monograph of the EP, the applicant can apply for a certificate of suitability that, where granted by the EDQM, shall be presented in the relevant section of the Module. Those certificates of suitability … are deemed to replace the relevant data of the corresponding sections described in the Module…

Dr. Susanne Keitel, 05/09/2009 ©2009 EDQM, Council of Europe, All rights reserved 8 Directive 2003/63/EC … The manufacturer shall give the assurance in writing to the applicant that the manufacturing process has not been modified since the granting of the certificate of suitability by the European Directorate for the Quality of Medicines.

Dr. Susanne Keitel, 05/09/2009 ©2009 EDQM, Council of Europe, All rights reserved 9 Options for Submitting API Information Certificate of suitability (CEP) Active Substance Master File (ASMF/EDMF) Substance Part of CTD

Dr. Susanne Keitel, 05/09/2009 ©2009 EDQM, Council of Europe, All rights reserved 10 NfG CHMP/QWP/297/97 rev. 1 corr “Summary of requirements for active substances in the quality part of the dossier” 2.1 Certificate of suitability Since this procedure requires a Ph. Eur. monograph, it is used for existing substances and the guideline states : “ where applicable, option 2.1 has the advantage of generally avoiding any subsequent reassessment ” 2.2 Active substance Master File (ASMF) 2.3 Full details of manufacture in licence application Since these procedures do not require a Ph. Eur. monograph they can be used for new substances; but may also be used for existing substances.

Dr. Susanne Keitel, 05/09/2009 ©2009 EDQM, Council of Europe, All rights reserved 11 Differences between CEP & ASMF -Scope: CEP : pharmacopoeial substances only, -> active substances or excipients ASMF : active substances only, -> new or pharmacopoeial

Dr. Susanne Keitel, 05/09/2009 ©2009 EDQM, Council of Europe, All rights reserved 12 Differences between CEP & ASMF -Specificity of ASMF: Full dossier sent by manufacturer of API to National authorities Applicants part sent by manufacturer of API to MA applicant or holder of medicinal Product Letter of access (to be sent by manufacturer of API) Assessment of ASMF by each national authority in the context of assessing a specific marketing authorisation application or variation for medicinal products

Dr. Susanne Keitel, 05/09/2009 ©2009 EDQM, Council of Europe, All rights reserved 13 Differences between CEP & ASMF -Assessment of CEP applications: Single evaluation centralised at EDQM By assessors nominated by national authorities Independent from marketing applications of medicinal products Certificate including annexes (additional tests to be performed) granted to manufacturer of active substance who supplies it to its users

Dr. Susanne Keitel, 05/09/2009 ©2009 EDQM, Council of Europe, All rights reserved 14 Certificate of Suitability Provides: Savings of time and resources Confidentiality of data (as ASMF): –Application submitted directly to EDQM by the applicant Facilitates management of marketing authorisation applications and variations CEP accepted in all Ph. Eur. commission countries (36) + others (eg. Canada ( MoU 03/2007 ), Australia, Morocco, Tunisia, New Zealand etc.)

Dr. Susanne Keitel, 05/09/2009 ©2009 EDQM, Council of Europe, All rights reserved 15 Regulatory background Directive 2003/63/EC and the various quality guidelines give options on how to fulfil the same basic requirements. The information required is the same regardless of the route selected (CEP or ASMF or marketing autorisation application)

Dr. Susanne Keitel, 05/09/2009 ©2009 EDQM, Council of Europe, All rights reserved 16 Scope of the Certification procedure -Substances described in monographs in the Ph. Eur. Active substances, excipients, herbal drugs / herbal preparations  “Chemical” CEP -Products with risk of TSE (SM, intermediates, reagents,..)  “TSE “CEP -Substances described in monographs in the Ph. Eur.and with risk of TSE  “Double “CEP Open to any manufacturer regardless of geographical origin

Dr. Susanne Keitel, 05/09/2009 ©2009 EDQM, Council of Europe, All rights reserved 17 Out of Scope of the Certification procedure -Biologicals -Human tissues derivatives -Finished products

Dr. Susanne Keitel, 05/09/2009 ©2009 EDQM, Council of Europe, All rights reserved 18 Certification: organisation Steering Committee Technical Advisory Boards (TAB) Chemical TSE Herbals Assessors Certification Secretariat

Dr. Susanne Keitel, 05/09/2009 ©2009 EDQM, Council of Europe, All rights reserved 19 Certification Steering Committee Chair Joint CHMP/CVMP Quality Working Party Chair CHMP Biologics Working Party Chair CVMP Immunologicals Working Party Chair Committee on Herbal Medicinal Products Chair GMP/GDP Inspectors Working Group Representative of EC Pharmaceutical Unit Representative of EMEA Chair European Pharmacopoeia Commission Chairs Technical Advisory Boards Representative of non-EU/EEA licensing authorities Director EDQM & Healthcare Possibility to co-opt relevant expert(s)

Dr. Susanne Keitel, 05/09/2009 ©2009 EDQM, Council of Europe, All rights reserved 20 Steering Committee - Role Monitor running of Certification procedure Appointment of assessors Appointment of Technical Advisory Boards (TABs) and their Chairpersons Definition of policy Review and comment on issues raised by TABs Co-ordination of issues between the represented parties

Dr. Susanne Keitel, 05/09/2009 ©2009 EDQM, Council of Europe, All rights reserved 21 Technical advisory boards (TABs) Consist of experienced assessors involved in the CEP procedure for a substantial time Role To take decisions on technical matter To assist assessors in case of doubt or disagreement To prepare technical guidance To identify technical/scientific problems and seek advice of SC

Dr. Susanne Keitel, 05/09/2009 ©2009 EDQM, Council of Europe, All rights reserved 22 Assessors and secretariat “Independent” Assessors (about 65 from 14 countries) –Role: evaluation of dossiers Certification Secretariat (EDQM scientific and administrative staff ) –Role : execution of the procedure and co- ordination

Dr. Susanne Keitel, 05/09/2009 ©2009 EDQM, Council of Europe, All rights reserved 23 New application requires: 1.Application form (for new application) 2.Signed Quality Overall Summary (+ e-version as Word file preferably) For templates of 1 & 2, visit: / Certification / New Applications 3.CV of expert who wrote QOS

Dr. Susanne Keitel, 05/09/2009 ©2009 EDQM, Council of Europe, All rights reserved 24 New application requires: 4.Dossier : 1 copy in English (preferably) or French CTD format Visit / Certification / New Applications : -Content of the Dossier for Chemical CEP (PA/PH/CEP (04) 1, 4R) : comparable to ASMF or 3.2.S of CTD

Dr. Susanne Keitel, 05/09/2009 ©2009 EDQM, Council of Europe, All rights reserved 25 New application requires: 4.Dossier (continued) : Visit / Certification / New Applications: -Content of a dossier for a substance for TSE risk assessment (PA/PH/CEP (06) 2) : requirements from Ph. Eur. general chapter (= EU nfg) -Content of a dossier for herbal drugs and herbal drugs preparation - quality evaluation (PA/PH/CEP 026) -Certificates of Suitability for sterile active substances (PA/PH/Exp. CEP/T (06) 13, 1R)

Dr. Susanne Keitel, 05/09/2009 ©2009 EDQM, Council of Europe, All rights reserved 26 Confidentiality Aspects CEP dossiers submitted directly by applicant –No applicant (open) part (≠ ASMF) Independent from any marketing authorisation application Archived in a specific restricted area (EDQM) Assessment on the premises of EDQM by two assessors appointed by the steering committee Certificate granted independently of any product licence application. Certificate may be supplemented with appropriate specific data and is only supplied to applicant

Dr. Susanne Keitel, 05/09/2009 ©2009 EDQM, Council of Europe, All rights reserved 27 How long does it take? Timeframes: –Applicant notified by EDQM on the assessment conclusion within 5 months of receipt of new dossier –Responses from applicant expected within 6 months for original demand –Applicant notified by EDQM on the assessment conclusion within 4 months of receipt of any response containing additional information –Responses from applicant expected within 3 months for any subsequent demand –…

Dr. Susanne Keitel, 05/09/2009 ©2009 EDQM, Council of Europe, All rights reserved 28 Certificates of Suitability > 3500 applications since procedure launched > 6400 certificates granted (includes revisions, renewals) ~ 2160 valid certificates > 760 substance monographs involved …

Dr. Susanne Keitel, 05/09/2009 ©2009 EDQM, Council of Europe, All rights reserved 29 Certificates of Suitability … > 900 manufacturers from 56 countries worldwide

Dr. Susanne Keitel, 05/09/2009 ©2009 EDQM, Council of Europe, All rights reserved 30 Certification: benefits Single assessment Harmonised assessment Replaces Active Substance Master File Savings of time and resources Updating of monographs (impurities) Revision of monographs (new or replacement test methods)

Dr. Susanne Keitel, 05/09/2009 ©2009 EDQM, Council of Europe, All rights reserved 31 The certificate of suitability : Certifies that the quality of a given substance can be suitably controlled by the PhEur monograph - with additional tests if necessary. It DOES NOT certify that a batch or batches of the substance complies with the Pharmacopoeia monograph. It IS NOT a GMP certificate

Dr. Susanne Keitel, 05/09/2009 ©2009 EDQM, Council of Europe, All rights reserved 32 Is a CEP valid ? / Databaseswww.edqm.eu / Databaseswww.edqm.eu

Dr. Susanne Keitel, 05/09/2009 ©2009 EDQM, Council of Europe, All rights reserved 33 Is a CEP valid ? Full CEP number Status Holder name Issue date of the current CEP

Dr. Susanne Keitel, 05/09/2009 ©2009 EDQM, Council of Europe, All rights reserved 34 Certification Inspection programme

Dr. Susanne Keitel, 05/09/2009 ©2009 EDQM, Council of Europe, All rights reserved 35 EU pharmaceutical legislation Marketing autorisation holder (MAH) responsible for the quality of the medicinal product MAH has to qualify/audit supplier(s) Qualified Person of manufacturer(s) to certify GMP compliant manufacture of all API used in marketing autorisation application and/or relevant variations

Dr. Susanne Keitel, 05/09/2009 ©2009 EDQM, Council of Europe, All rights reserved 36 Certification Inspections In application of Directive 2001/83/EC as amended (Article 111) and Directive 2001/82/EC as amended (Article 80) A Mandate is given to EDQM (by EC) to establish an annual programme for inspections –Inspection inside and outside Europe –Manufacturing sites and brokers/distributors holding CEPs –Authorities to be notified of issues arising

Dr. Susanne Keitel, 05/09/2009 ©2009 EDQM, Council of Europe, All rights reserved 37 Exchanging information/advice, communication opportunities

Dr. Susanne Keitel, 05/09/2009 ©2009 EDQM, Council of Europe, All rights reserved 38 General questions on CEP procedure & its requirements ?

Dr. Susanne Keitel, 05/09/2009 ©2009 EDQM, Council of Europe, All rights reserved 39 Technical Advice meeting Possible i.e. when need to clarify requirements of CEP procedure / complex schemes / specific questions: –prior to or during the submission of an application for a new CEP or for its subsequent revision or renewal –To meet CEP Division representatives –Need to apply in advance (at least 1 month) –Procedure and application form on the web –1-2 sessions/month at EDQM premises (written response, or telephone conference may also be possible) –Fee of 1000 euros / Meeting length  1 hour

Dr. Susanne Keitel, 05/09/2009 ©2009 EDQM, Council of Europe, All rights reserved 40 Technical Advice meeting

Dr. Susanne Keitel, 05/09/2009 ©2009 EDQM, Council of Europe, All rights reserved 41 One-to-One meetings -Same scope as technical advice meeting -but organised during a conference or an exhibition -Meeting length generally 15 to 30 minutes -Registration at least 1 week before event -Procedure and application form on the web - specific for each event -Fee specific for each event

Dr. Susanne Keitel, 05/09/2009 ©2009 EDQM, Council of Europe, All rights reserved 42 One-to-One meetings -Check “ Events ” pages of EDQM website

Dr. Susanne Keitel, 05/09/2009 ©2009 EDQM, Council of Europe, All rights reserved 43 Acknowledgements My special thanks to my colleagues from the Certification Division at the EDQM: Corinne Pouget Hélène Bruguera Patricia Oelker And all the other 30 staff members of the CEP division

Thank you!